Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Candidemia and invasive candidiasis represent critical healthcare-associated fungal infections that pose substantial challenges to medical systems worldwide. These conditions arise when fungi from the Candida genus infiltrate the bloodstream or deeper tissues, leading to a range of clinical manifestations. Among the various species, continues to hold its position as the most frequently encountered causative agent, largely due to its prevalence and adaptability within human hosts. However, it is far from the only significant player; other Candida species, such as , , and the particularly concerning , contribute significantly to the disease burden and exhibit varying dominance depending on geographic regions. The clinical presentation of these infections can differ widely, spanning from subtle, almost imperceptible symptoms in some patients to severe, life-threatening fulminant sepsis in others, often accompanied by alarmingly high mortality rates that underscore the urgency of effective management strategies. Several well-established risk factors predispose individuals to developing invasive candidiasis and candidemia. Breaches in the body's natural barriers-such as the skin (cutaneous) or the gastrointestinal (GI) tract-provide entry points for these opportunistic pathogens. Additionally, deficiencies in the host's immune responses, whether due to medical treatments, underlying diseases, or genetic predispositions, heighten vulnerability to infection. Among the diverse Candida species, has emerged as an especially troubling entity in recent years. This multidrug-resistant species is notorious for its resistance to standard antifungal therapies, which complicates treatment efforts and contributes to elevated morbidity and mortality rates. Its rapid global spread has positioned it as a formidable public health threat, prompting heightened surveillance and research into its behavior and control.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026337PMC
http://dx.doi.org/10.3390/diseases13040093DOI Listing

Publication Analysis

Top Keywords

invasive candidiasis
12
candidemia invasive
8
candida species
8
mortality rates
8
comprehensive review
4
review candidemia
4
candidiasis adults
4
adults focus
4
focus emerging
4
emerging multidrug-resistant
4

Similar Publications

Introduction: Candida auris is a yeast that has a high mortality rate in critically ill patients and is resistant to many antifungal agents enhancing its clinical importance. Our study identifies the risk factors for C. auris invasive infection, antifungal susceptibility, and outcomes.

View Article and Find Full Text PDF

Purpose Of Review: In candidemia, the standard 14-day antifungal treatment after blood culture clearance has been long accepted, despite being based on limited and outdated evidence. This review discusses the rationale for re-evaluating treatment duration, in the context of growing interest in optimizing antifungal use.

Recent Findings: A small number of retrospective studies have explored shorter treatment courses in uncomplicated candidemia, suggesting similar outcomes in terms of mortality and recurrence compared to the traditional 14-day regimen.

View Article and Find Full Text PDF

Objectives: (formerly ) is a leading cause of invasive candidiasis and rapidly develops antifungal drug resistance during treatment. An increasing number of clinical isolates shows reduced susceptibility to echinocandins and azoles, leaving amphotericin B (AMB) as a last therapeutic option. Resistance of to this drug is rare and its underlying mechanisms are still not fully understood.

View Article and Find Full Text PDF

Unlabelled: Vulvovaginal candidiasis is a very common human fungal infection. Most are successfully treated with antifungal drugs, yet ~8% lead to recurrent vulvovaginal candidiasis (RVVC). Vaginal and rectal populations have been previously found to be closely related in RVVC.

View Article and Find Full Text PDF

To evaluate the diagnostic performance of the 1,3-β-D-glucan (BDG) test and the galactomannan (GM) antigen test in invasive fungal infections (IFI) among hematologic patients and to explore an optimized diagnostic approach. A total of 294 consecutive patients with hematological diseases suspected of fungal infections were enrolled at Peking University People's Hospital from January 2020 to October 2023. IFI diagnosis referred to a composite reference standard (CRS), which combined both mycological and clinical evidence.

View Article and Find Full Text PDF